In 2022, the global anatomic pathology market was valued at USD 30.16 billion, and it is projected to expand at a compound annual growth rate (CAGR) of 8.7% from 2023 to 2030. This growth is largely driven by the increasing integration of biomarkers in clinical applications, enabling pathologists to explore molecular-level insights. By revealing detailed mechanisms, biomarkers aid significantly in making more informed clinical decisions and ultimately contribute to better patient outcomes. Consequently, there is a growing dependency on biomarker-based pathology tests and procedures to investigate common cancers and tumor development, which in turn is fueling the market's expansion.

Another major factor supporting the market’s growth is the widespread adoption of advanced pathology equipment, such as digital microscopes, gross imaging systems, and staining systems. These technological advancements, particularly digital imaging solutions, offer superior specificity and accuracy over traditional pathology techniques. The demand for these digital solutions is increasing as they provide a higher level of diagnostic accuracy and reliability, thus driving their adoption in anatomic pathology practices and contributing to the overall growth of the market.

Companies in the anatomic pathology sector are continuously innovating to develop advanced and user-friendly pathology equipment. These efforts focus on enhancing design features and usability to improve diagnostic precision and efficiency. A notable example is OptraScan, a provider specializing in comprehensive digital pathology solutions and scanners for applications like confocal, fluorescence, frozen sections, and brightfield imaging. In May 2021, OptraScan introduced CytoSiA, an advanced digital solution aimed at streamlining the scanning and analysis of liquid-based cytology slides and pap smears.

Gather more insights about the market drivers, restrains and growth of the Anatomic Pathology Market

Regional Insights

North America:

North America led the global anatomic pathology market, capturing the largest revenue share of 44.9% in 2022. This region is expected to maintain its dominant position throughout the forecast period. The substantial market share is attributed to the presence of established industry leaders, the expanding adoption of digital pathology services equipped with advanced imaging technologies, increased awareness about the importance of routine health screenings, and supportive government reimbursement policies. Major companies are actively working to reinforce their market share, particularly within the U.S. For example, in September 2021, Agilent Technologies partnered with Visiopharm to expand its AI-driven precision pathology software on a global scale. Such collaborations are expected to boost market growth by advancing diagnostic capabilities. Additionally, in April 2021, Abbott Laboratories collaborated with Walgreens Boots Alliance to offer accessible healthcare services in the U.S., including affordable medical consultations and diagnostic testing. These initiatives reflect efforts to broaden healthcare reach and make diagnostic services more widely available, further driving growth in the region.

Asia Pacific:

The Asia Pacific region is anticipated to experience the fastest growth, with a projected CAGR of 11.6% from 2023 to 2030. The anatomic pathology market in China is seeing rapid development, driven by numerous pathology congresses held in recent years. These events, such as the 2nd Digital Pathology AI Congress: China, scheduled for September 2022, aim to increase the adoption of digital pathology solutions, enhance workflow efficiency, and standardize image analysis across the region. The emphasis on digital pathology and AI integration is expected to drive significant advancements in diagnostic accuracy and operational efficiency, further accelerating the market's growth in Asia Pacific.

Browse through Grand View Research's Clinical Diagnostics Industry Research Reports.

• The tissue diagnostics market sizewas estimated at USD 8.72 billion in 2024 and is projected to grow at a CAGR of 8.41% from 2025 to 2030
  
  
• The global blood collection market sizewas estimated at USD 3.73 billion in 2024 and is projected to grow at a CAGR of 8.7% from 2024 to 2030.

Key Companies profiled:

Anatomic pathology is a mature industry with a large number of key players in it. The advent of new strategic plans to maintain competitiveness stimulates market growth. 

Some prominent players in the global anatomic pathology market include:

• Danaher
• PHC Holdings Corporation
• Quest Diagnostics Incorporated
• Laboratory Corporation of America Holdings
• Hoffmann-La Roche AG
• Agilent Technologies, Inc.
• Cardinal Health
• Sakura Finetek USA, Inc.
• NeoGenomics Laboratories, Inc.
• BioGenex
• Bio SB

Order a free sample PDF of the Market Intelligence Study, published by Grand View Research.